Download PDF
Thromb Haemost 1975; 33(01): 026-037
DOI: 10.1055/s-0038-1647807
Meeting of the International Committee on Thrombosis and Haemostasis — Symposium on Heparin, Basel, Switzerland, September, 1974
Schattauer GmbH

Pharmacokinetics of Heparin[*]

Distribution and Elimination
J Worth Estes
1   Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 80 East Concord Street, Boston, Massachusetts 02118
,
Paul F Poulin
1   Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, 80 East Concord Street, Boston, Massachusetts 02118
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2018 (online)

    Permissions and Reprints

 

* Presented at the Symposium on Heparin, Basel, Switzerland, September, 1974.


 

  • References

  • 1 Adolph E. R. Quantitative relations in the physiological constitutions of mammals. Science 1949; 109: 579.
    CrossrefPubMedGoogle Scholar
  • 2 Benaoerraf B, Miesoher P. Bacterial phagocytosis by the reticuloendothelial system in vivo under different immune conditions. Annals of the New York Academy of Sciences 1960; 88: 184.
    PubMedGoogle Scholar
  • 3 Blakeley J. A. A rapid bedside method for the control of heparin therapy. Canadian Medical Association Journal 1968; 99: 1072.
    PubMedGoogle Scholar
  • 4 Eiber H. B, Danishefsky I, Borelli F. Studies made with radioactive heparin in humans. Angiology 1960; 11: 40.
    CrossrefPubMedGoogle Scholar
  • 5 Estes J. W. (Letter to the editor) New England Journal of Medicine. 1968; 279: 887
    PubMedGoogle Scholar
  • 6 Estes J. W, Pelikan E. W, Kruger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clinical Pharmacology and Therapeutics 1969; 10: 329.
    PubMedGoogle Scholar
  • 7 Estes J. W. Kinetics of the anticoagulant effect of heparin. Journal of the American Medical Association 1970; a 212: 1492.
    CrossrefPubMedGoogle Scholar
  • 8 Estes J. W. (Letter to the editor) Journal of the American Medical Association. 214 1970; b 1122
    PubMedGoogle Scholar
  • 9 Estes J. W, Pelikan E. W. Dose and effect metameters in clinical use of heparin. Pharmacologist 1971; 13: 317.
    PubMedGoogle Scholar
  • 10 Estes J. W. The heterogeneity of the anticoagulant response to heparin. Journal of Clinical Pathology 1972; 25: 45.
    CrossrefPubMedGoogle Scholar
  • 11 Hoch H, Chanutin A. Effects of anticoagulants on serum and plasma. Journal of Biological Chemistry 1952; 197: 503.
    PubMedGoogle Scholar
  • 12 Jaques L. B, Bell H. J. Determination of heparin. Methods of Biochemical Analysis 1951; 7: 253.
    PubMedGoogle Scholar
  • 13 Kruger-Thiemer E. Formal theory of drug dosage regimens. Journal of Theoretical Biology 1966; 13: 212.
    CrossrefPubMedGoogle Scholar
  • 14 Kruger-Thiemer E. Pharmacokinetics and dose-concentration relationships. In: Physico-Chemical Aspects of Drug Actions: 63. Pergamon Press; New York.: 1968
    Google Scholar
  • 15 Levy G. Kinetics of pharmacologic effects. Clinical Pharmacology and Therapeutics 1966; 7: 362.
    PubMedGoogle Scholar
  • 16 McGovern J. J, Bunker J. P, Goldstein R, Estes J. W. Effect of conjugated estrogens on the coagulation mechanism. Journal of the American Medical Association 1961; 175: 1011.
    CrossrefPubMedGoogle Scholar
  • 17 Monkhouse F. C. Physiological factors concerned with the removal of injected heparin from the circulating blood. American Journal of Physiology 1954; 178: 223.
    PubMedGoogle Scholar
  • 18 Newman E. V, Bordley J, Winternitz J. The interrelationships of glomerular filtration rate (mannitol clearance), extracellular fluid volume, surface area of the body and plasma concentration of mannitol. Bulletin of the John Hopkins Hospital 1944; 75: 253.
    PubMedGoogle Scholar
  • 19 Olsson P, Lagergren H, Eκ S. The elimination from plasma of intravenous heparin. Acta Medica Scandinavica 1963; 173: 619.
    PubMedGoogle Scholar
  • 20 Padawer J. Conference on Mast Cells and Basophils. Annals of the New York Academy of Sciences 103: 1-492. passim. 1963;
    PubMedGoogle Scholar
  • 21 Rodman Jr. N. F, Barrow E. M, Graham J. B. Diagnosis and control of the hemophiloid states with the partial thromboplastin time (PTT) test. American Journal of Clinical Pathology 1958; 29: 525.
    CrossrefPubMedGoogle Scholar
  • 22 Rosenberg R. D, Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. Journal of Biological Chemistry 1973; 248: 6490.
    PubMedGoogle Scholar
  • 23 Siegelman A. M, Carlson A. S, Robertson T. Investigation of serum trypsin and related substances. Archives of Biochemistry and Biophysics 1962; 97: 159.
    CrossrefPubMedGoogle Scholar
  • 24 Spector I, Corn M. Control of heparin therapy with activated partial thromboplastin times. Journal of the American Medical Association 1967; 201: 157.
    CrossrefPubMedGoogle Scholar
  • 25 Yin E. T, Wessler S, Stoll P. J. Biological properties of the naturally occuring plasma inhibitor to activated factor X. Journal of Biological Chemistry 1971; 246: 3703.
    PubMedGoogle Scholar